TGN 212Alternative Names: Anticoagulant antidote; Anticoagulant neutralising agent; TGN212
Latest Information Update: 16 Apr 2010
At a glance
- Originator Trigen Holdings AG
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Vascular injuries
Most Recent Events
- 31 May 2005 ProCorde GmbH has merged with Trigen Holdings plc to form Trigen Holdings AG